SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Sees Significant Increase in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 2,500 shares, a growth of 2,400.0% from the October 31st total of 100 shares. Based on an average trading volume of 15,200 shares, the days-to-cover ratio is currently 0.2 days.

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock remained flat at $0.07 during trading hours on Wednesday. 5,216 shares of the company’s stock traded hands, compared to its average volume of 19,303. The stock has a 50-day simple moving average of $0.05 and a 200-day simple moving average of $0.04. SAB Biotherapeutics has a twelve month low of $0.01 and a twelve month high of $0.19.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.